Cargando…

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study

BACKGROUND: Optimal peptide concentration in treatment with (177)Lu-DOTATOC/DOTATATE is a matter of debate. Most of the studies with peptide receptor radionuclide therapy mention peptide dose ranging between 100 and 250 μg. The aim of this is to identify possible differences in radiation-absorbed do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, Vikas, Prasad, Sonal, Lehnert, Wencke, Brenner, Winfried, Kai, Huang, Bronzel, Marcus, Kluge, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771073/ https://www.ncbi.nlm.nih.gov/pubmed/35125759 http://dx.doi.org/10.4103/ijnm.ijnm_15_21

Ejemplares similares

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC
por: Gühne, Falk, et al.
Publicado: (2021)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy
por: Ardenfors, Oscar, et al.
Publicado: (2022)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC
por: Kramer, Vasko, et al.
Publicado: (2020)

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results
por: Baum, Richard P., et al.
Publicado: (2022)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy
por: Eberlein, Uta, et al.
Publicado: (2015)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Kidney Dosimetry in (177)Lu and (90)Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
por: Guerriero, F., et al.
Publicado: (2013)

Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021)

SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a (177)Lu-DOTA-Integrin αvβ6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model
por: Sachindra, Sachindra, et al.
Publicado: (2021)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent (177)Lu-DOTATOC therapy
por: Goetz, Th. I., et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA
por: Prasad, Vikas, et al.
Publicado: (2021)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Clinical Issues Related to Fluid Management during (177)Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease
por: Arora, Saurabh, et al.
Publicado: (2018)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Deadtime effects in quantification of (177)Lu activity for radionuclide therapy
por: Uribe, Carlos F., et al.
Publicado: (2018)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
por: Thapa, Pradeep, et al.
Publicado: (2017)

Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
por: Jiang, Yuanyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ecl9rp3nohfh3ovl1ecvvmuv5f